8-K: 89bio Announces Second Quarter 2024 Financial Results and Appoints New Board Member

89bio reported its Q2 2024 financial results, initiated two Phase 3 trials for MASH, and appointed Dr. Charles McWherter to its Board of Directors.

Summary

• 89bio announced its financial results for the second quarter of 2024, reporting a net loss of $48.0 million, compared to a net loss of $38.4 million for the same period in 2023.
• The company's research and development expenses increased to $44.9 million, up from $34.9 million in the prior year, driven by clinical development and manufacturing costs.
• General and administrative expenses also rose to $8.6 million from $7.2 million, due to increased professional fees and personnel costs.
• 89bio initiated two Phase 3 trials for pegozafermin, ENLIGHTEN-Fibrosis for non-cirrhotic MASH and ENLIGHTEN-Cirrhosis for MASH with compensated cirrhosis, each enrolling approximately 760 patients.
• The company's cash, cash equivalents, and marketable securities totaled $531.4 million as of June 30, 2024, with an additional $24.7 million received after the quarter end from warrant exercises.
• Dr. Charles McWherter was appointed to the Board of Directors, effective July 30, 2024, bringing extensive experience in drug development and liver disease.
• The Phase 3 ENTRUST trial for severe hypertriglyceridemia (SHTG) is ongoing, with topline data expected in 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and the appointment of a key board member, but tempered by the increased net loss and operating expenses.

Positives

• The initiation of two Phase 3 trials for MASH demonstrates significant progress in the development of pegozafermin.
• The appointment of Dr. Charles McWherter to the Board of Directors brings valuable expertise in drug development and liver disease.
• The company has a strong cash position of $531.4 million, providing financial stability for ongoing clinical trials.
• The ENLIGHTEN-Cirrhosis trial design includes a 24-month assessment for fibrosis regression, potentially leading to accelerated approval.
• The company is actively preparing for the potential commercialization of pegozafermin, including manufacturing readiness.

Negatives

• The company reported a net loss of $48.0 million for the second quarter of 2024, an increase from $38.4 million in the same period of 2023.
• Research and development expenses increased significantly to $44.9 million, driven by clinical trial costs.
• General and administrative expenses also increased to $8.6 million, due to higher professional fees and personnel costs.

Risks

• The success of pegozafermin is critical to the company's future, and clinical trial results may not be predictive of future outcomes.
• The company faces competition from other companies developing treatments for MASH and SHTG.
• The company's ability to raise additional capital is subject to market conditions and other factors.
• The timing and outcome of the Phase 3 trials are subject to various risks and uncertainties.

Future Outlook

The company anticipates topline results from the ENTRUST Phase 3 trial in SHTG in 2025 and is focused on advancing its Phase 3 trials for MASH, with potential for accelerated approval based on fibrosis regression data.

Management Comments

• Rohan Palekar, CEO of 89bio, stated that they are thrilled to have initiated two pivotal Phase 3 trials addressing non-cirrhotic MASH and MASH with compensated cirrhosis.
• Rohan Palekar also mentioned that they continue to take important steps forward that they believe will strategically enhance their preparedness for potential commercialization of pegozafermin.
• Dr. McWherter stated that he is honored to join 89bio's Board and looks forward to contributing to the company's strategic goals.

Industry Context

This announcement comes as the biopharmaceutical industry is increasingly focused on developing treatments for liver and cardiometabolic diseases, particularly MASH and SHTG. 89bio's progress in Phase 3 trials positions them as a key player in this space.

Comparison to Industry Standards

• The initiation of two Phase 3 trials for MASH is a significant step, comparable to other companies like Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX) who are also advancing MASH treatments.
• The focus on both non-cirrhotic and cirrhotic MASH patients is notable, as many companies are primarily targeting earlier stages of the disease.
• The cash position of $531.4 million is relatively strong for a clinical-stage company, providing a runway for ongoing trials, similar to other companies in the space such as Akero Therapeutics (AKRO).
• The increase in R&D expenses is typical for a company in Phase 3 development, and the net loss is consistent with other clinical-stage biopharmaceutical companies.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials but concerned about the increased net loss.
• Employees may be impacted by the increased headcount and operational expansion.
• Patients with MASH and SHTG may benefit from the potential approval of pegozafermin.
• Suppliers and contract manufacturers may see increased business opportunities due to the ongoing clinical trials.

Next Steps

• Continue enrollment in the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials for MASH.
• Continue enrollment in the ENTRUST Phase 3 trial for SHTG.
• Prepare for potential commercialization of pegozafermin.
• Report topline results from the ENTRUST trial in 2025.

Key Dates

Keywords

Pegozafermin, MASH, SHTG, Clinical Trials, Phase 3, Fibrosis, Hypertriglyceridemia, Biopharmaceutical, Board of Directors, Financial Results